Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 trial (BIRD-1) for BEST1-associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, with Month 3 data expected in the second week of September 2026. The company plans to present at EURETINA in October 2026 and submit Month 3 results to the FDA for next steps.
How this was made
The 30-second read
Why it matters
The company provides a detailed path to next steps: IDMC review after Month 3, planned FDA alignment on next development steps, and potential expansion into Cohort 2 or a pivotal trial depending on OCT fluid reduction and safety.
Market read
This is a milestone-setting clinical update that can influence positioning ahead of September topline data, especially given the quiet period and the stated decision framework for dose escalation.
What to watch
Open-label design and small Cohort 1 size (five participants) may reduce confidence in any OCT percentage targets; investors may discount the “clinically meaningful” 20% threshold without actual observed outcomes.
Background
Opus Genetics is running an adaptive, open-label Phase 1/2 trial (BIRD-1) for OPGx-BEST1 in BEST-1 associated inherited retinal diseases, with Cohort 1 dose 1.5E9 vg/eye completed in May 2026.
Ticker impact
Opus Genetics (IRD) updates its OPGx-BEST1 Phase 1/2 trial, including Cohort 1 completion, Month 3 review, and September 2026 topline timing.
Moderate upside bias into September if investors view the planned OCT and functional readouts as de-risking, with volatility around the quiet period.
This is a primary, company-specific clinical development timeline update with explicit next milestones, but it does not disclose Cohort 1 results yet, limiting immediate fundamental repricing.
Market effects
Reinforces investor focus on AAV retinal gene therapy programs and the market’s attention to OCT structural target engagement as a dose-escalation decision input.
Limited direct regional impact; primarily affects US-listed biotech sentiment and clinical-trial risk appetite.
EURETINA presentation in Vienna can broaden European investor visibility, potentially influencing cross-Atlantic biotech sentiment ahead of topline data.
Counterpoint
Because the release provides timing and endpoints but no efficacy/safety datapoints, the market may treat it as routine and fade the move until Month 3 results are actually reported.
Key entities
- companyOpus Genetics, Inc.
Clinical-stage gene therapy company developing OPGx-BEST1 for BEST-1 associated inherited retinal diseases.
- programOPGx-BEST1
AAV-based gene therapy targeting BEST1 gene delivery to retinal pigment epithelium for BVMD and ARB.
- clinical_trialBIRD-1 (Phase 1/2)
Adaptive, open-label study evaluating safety and efficacy with dose escalation across Cohort 1 and Cohort 2.
- committeeIDMC
Independent Data Monitoring Committee that will review Cohort 1 data after Month 3.
- regulatorFDA
Planned to receive Month 3 data for alignment on next clinical development steps.
